Enlivex Therapeutics
Open
Market Cap
High
Low
Close
Volume
P/E Ratio
Div/Yield
About Enlivex Therapeutics
Enlivex Therapeutics Ltd.是一家臨床階段的巨噬細胞重編程免疫治療公司。它正在開發 Allocetra，一種基於細胞的療法，用於治療與敗血症相關的器官功能障礙和衰竭，目前正在進行 II 期臨床試驗，以及治療實體瘤的臨床前試驗。 Enlivex Therapeutics Ltd.成立於2005年，總部位於以色列內斯錫奧納。
如何購買 Enlivex Therapeutics (ENLV)
登入
1分鐘開戶
僅需1分鐘即可完成帳戶申請和驗證。整個過程完全自助，支援 RockFlow App 和網頁端操作。
充值資金
帳戶驗證完成後，您可以使用首選的支付方式向帳戶充值。
購買 ENLV
透過 RockFlow App 或網頁端搜尋 ENLV，輸入您想要投資的金額，然後點擊確認即可完成交易。
© Rockalpha Limited. All Rights Reserved.
Rockalpha Limited is registered on the New Zealand Financial Service Providers Register(FSP: 1001454). Rockalpha Limited's Financial Service Providers registration can be verified on the Financial Service Providers Register. Rockalpha Limited is a member of the Insurance & Financial Services Ombudsman Scheme, an independent dispute resolution service provider. Rockalpha Limited is not licensed by a New Zealand regulator to provide the client money or property services, and Rockalpha Limited’s registration on the New Zealand register of financial service providers or membership of the Insurance & Financial Services Ombudsman Scheme does not mean that Rockalpha Limited is subject to active regulation or oversight by a New Zealand regulator.Rockalpha Limited is registered on the New Zealand Financial Service Providers Register(FSP: 1001454). Rockalpha Limited's Financial Service Providers registration can be verified on the Financial Service Providers Register. Rockalpha Limited is a member of the Insurance & Financial Services Ombudsman Scheme, an independent dispute resolution service provider.